Commissioning post show updated | Page 28

www.healthpluscare.com/commissioning A NICE APPROVED QIPP PROJECT WHICH HAS BEEN ROLLED OUT BY SOUTH WORCESTERSHIRE CCG HAS RESULTED IN COST SAVINGS, GP DR DAVID FARMER TELLS THE COMMISSIONING SHOW. The QIPP approved case study was conducted in the arena of Ulcerative Colitis, a long term remitting and relapsing disease which can seriously impact on the patient’s health, social and employment opportunities and overall quality of life. A major part of treatment of UC centres around effective disease management, including adherence to drug therapy with the specific aims of inducing and maintaining disease remission, reducing steroid intake and minimising, hospital outpatient and inpatient treatment,’ explains Dr Farmer. ‘Conversely poor disease management and low adherence to drug therapy is closely associated with poor outcomes and high costs. Indeed 75% of all NHS spend is on UC patients who are inadequately controlled and go on to require intensive medical or surgical intervention. ‘As a GP I know just how this disease impacts not just on the patient but also on family members and the toll it can take on every area of daily life.’ The QIPP pilot project, which was supported by Dr Falk Pharma UK but independently designed and managed by Medicines Management Solutions (MMS) initially reviewed 363 patients with UC across 11 GP practices in Leicestershire, recommended a change in 130 and actioned change in 87, including changing from multiple daily medication to once a day Salofalk 1.5g Granules. Six months after the changes, routine hospital visits were down by 47%, hospital visits due to flare-ups were down by 60%, GP visits due to flare up down by 44% and there was a 50% reduction in steroid courses prescribed. Overall the cost saving was conservatively estimated at £30,000. The figures were later presented to and accepted by NICE as a QIPP case study. ‘When we in South Worcester CCG were offered this QIPP case study for consideration for roll out, it seemed like an excellent opportunity,’ says Dr Farmer. ‘Firstly we are always looking for value for money and the pilot already provided quite stunning figures to support this. In addition, the methodology had clearly been very well thought out and showed in-depth knowledge of the issues surrounding UC, such as flare 28 ups and hospital visits, and drug nonadherence. We were delighted too, to receive the support of MMS, although we note that this may not always be practicable or desirable for CCG’s in other regions.’ The project was rolled out across 32 South Worcestershire GP practices early this year, (with another 2 local CCGs to follow later this year). In total 481 patients were reviewed, 279 were invited to clinic and interventions were made in 76 patients with an estimated cost saving of £27,027.’ Dr Farmer is extremely pleased with these early results. ‘GP’s are very busy people and although we may have good ideas for saving money and improving patient quality of life, actually getting these ideas put into practise is often very time consuming and expensive. So to be able to take an ‘off the peg’ study like this, where there was already an established structure and methodology and proven cost effectiveness was a joy. ‘Apart from the cost savings, the study also promoted excellent medical practise even before being implemented. We all know how easy it is for some patients to fall through the gaps of our busy healthcare services and perhaps not be reviewed as often as they should. Often the very act of reviewing a patient, and spending time discussing with them how best to manage their condition including adherence to therapy empowers and encourages them to self manage in a more effective way. ‘In supporting and encouraging thorough review, intervention and patient engagement, this study is actually a template for very good medicine which could be used for other chronic and costly disease such as diabetes and heart disease.’